CSPC PHARMA (01093) has announced that the Aprepitant Injection (4.4ml:32mg) developed by the group has obtained a drug registration certificate issued by the National Medical Products Administration of China. This product is a new-generation NK-1 receptor antagonist formulated as a submicron emulsion injection. It works by selectively binding to and antagonizing substance P at NK-1 receptors in the brain, effectively preventing both acute and delayed vomiting. The injection is indicated for the prevention of postoperative nausea and vomiting (PONV) in adults. Compared to traditional formulations of aprepitant, this product offers a rapid onset of action, significantly improves patient compliance, and effectively reduces the incidence of allergic reactions in clinical use, providing a superior option for preventing PONV in adults. In September 2024, the group's Aprepitant Injection (18ml:130mg) also received a drug registration certificate, which is primarily indicated for preventing chemotherapy-induced nausea and vomiting. The successful approval of this product further strengthens the group's competitive position in the antiemetic market.